PMID- 23793275
OWN - NLM
STAT- MEDLINE
DCOM- 20130827
LR  - 20221207
IS  - 0353-5053 (Print)
IS  - 0353-5053 (Linking)
VI  - 25
IP  - 2
DP  - 2013 Jun
TI  - Different serum BDNF levels in depression: results from BDNF studies in FYR 
      Macedonia and Bulgaria.
PG  - 123-7
AB  - BACKGROUND: A growing body of evidence shows that brain-derived neurotrophic 
      factor (BDNF) plays a role in depressive disorder. Serum BDNF levels are lower in 
      depressed patients and they increase after a long course of antidepressant 
      treatment. Our study aims to test the effect of antidepressant treatment on serum 
      BDNF levels in patients with a depressive episode, after they have achieved 
      remission in two studies in Macedonia and Bulgaria. SUBJECTS AND METHODS: In the 
      Macedonian study 23 patients were included (11 female, 12 male) diagnosed with a 
      first depressive episode according to ICD-10, as well as 23 control subjects age- 
      and sex-matched without a history of psychiatric disorder. In the Bulgarian study 
      10 female patients with depression and 10 control subjects were included. We have 
      applied the Hamilton Depression Rating Scale (HDRS) to assess depression 
      severity. Blood samples were collected before antidepressive treatment and after 
      remission was achieved (decrease to 7 points or less on HDRS). RESULTS: In the 
      Macedonian study, mean serum BDNF level at baseline was 13.15+/-6.75 ng/ml and the 
      mean HDRS score was 28.52+/-4.02. Untreated depressed patients showed significantly 
      lower serum BDNF levels compared to the control group (25.95+/-9.17 ng/ml). After 
      remission was achieved, the mean serum BDNF level was 24.73+/-11.80 ng/ml whereas 
      the mean HDRS score was 7.04+/-3.15. After 8 weeks of treatment there was no 
      statistically significant difference in the serum BDNF levels between the two 
      groups. In the Bulgarian study, baseline mean serum BDNF levels were 26.84+/-8.66 
      ng/ml, after 3 weeks treatment and remission was achieved mean serum BDNF levels 
      were 30.33+/-9.25 ng/ml and in the control group mean serum BDNF levels were 
      25.04+/-2.88 ng/ml. Integrated results showed baseline mean serum BDNF levels of 
      17.30+/-9.66 ng/ml, after achieved remission 26.43+/-11.25 ng/ml and in the control 
      group mean serum BDNF levels of 25.68+/-7.76 ng/ml. CONCLUSION: The Bulgarian 
      results showed no statistical difference between the depressed group and 
      controls. The Integrated results and the Macedonian study supported previous 
      findings of low BDNF levels in untreated depressive patients compared to healthy 
      controls, and that those levels increase after antidepressant treatment. These 
      results may suggest that low serum levels of BDNF are a state abnormality that is 
      evident during depression and normalizes during remission.
FAU - Ristevska-Dimitrovska, Gordana
AU  - Ristevska-Dimitrovska G
AD  - Higher Medical School Bitola, University, St. Kliment Ohridski, Bitola, Vasko 
      Karangjelevski bb, 7000 Bitola, FYR Macedonia. gordana.md@gmail.com
FAU - Shishkov, Rinaldo
AU  - Shishkov R
FAU - Gerazova, Vesna Pejoska
AU  - Gerazova VP
FAU - Vujovik, Viktorija
AU  - Vujovik V
FAU - Stefanovski, Branislav
AU  - Stefanovski B
FAU - Novotni, Antoni
AU  - Novotni A
FAU - Marinov, Petar
AU  - Marinov P
FAU - Filov, Izabela
AU  - Filov I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Croatia
TA  - Psychiatr Danub
JT  - Psychiatria Danubina
JID - 9424753
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cyclohexanols)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 41VRH5220H (Paroxetine)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain-Derived Neurotrophic Factor/*blood/drug effects
MH  - Bulgaria
MH  - Cyclohexanols/pharmacology/therapeutic use
MH  - Depressive Disorder/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Paroxetine/pharmacology/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Republic of North Macedonia
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology/therapeutic use
MH  - Sertraline/pharmacology/therapeutic use
MH  - Treatment Outcome
MH  - Venlafaxine Hydrochloride
MH  - Young Adult
EDAT- 2013/06/26 06:00
MHDA- 2013/08/28 06:00
CRDT- 2013/06/25 06:00
PHST- 2013/06/25 06:00 [entrez]
PHST- 2013/06/26 06:00 [pubmed]
PHST- 2013/08/28 06:00 [medline]
PST - ppublish
SO  - Psychiatr Danub. 2013 Jun;25(2):123-7.